-
Ocrelizumab, sold
under the
brand name Ocrevus, is a
medication used for the
treatment of
multiple sclerosis (MS). It is a
humanized anti-CD20 monoclonal...
-
continue to
emerge in
modern medicine. In
March 2017, the FDA
approved ocrelizumab as a
treatment for
primary progressive MS in adults, the
first drug to...
-
Research (2020-01-24). "New Drug
Therapy Approvals 2019". FDA. "Ocrevus (
ocrelizumab) Injection". www.accessdata.fda.gov.
Retrieved 2021-07-01. "Search Orphan...
- deficiency,
later discontinued in 2004 and
replaced by
Nutropin AQ.
Ocrevus (
ocrelizumab), for MS. Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for...
-
monoclonal treatment, in
managing this disease,
other anti-CD20
drugs such as
ocrelizumab, veltuzumab, and
ofatumumab have been
explored as
potential treatments...
- antigen. CD20 is the
target of the
monoclonal antibodies rituximab,
ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab...
-
Belimumab L04AG05
Vedolizumab L04AG06
Alemtuzumab L04AG07
Begelomab L04AG08
Ocrelizumab L04AG09
Emapalumab L04AG10
Inebilizumab L04AG11
Anifrolumab L04AG12 Ofatumumab...
-
Study to
Evaluate the
Efficacy and
Safety of
Fenebrutinib Compared With
Ocrelizumab in
Adult Patients With
Primary Progressive Multiple Sclerosis" at ClinicalTrials...
-
cancer indication due to
promising phase II results. 2017:
Ocrevus (
ocrelizumab): The
first FDA-approved
therapy that
treats both relapsing-remitting...
- has led to some
other anti-CD20
monoclonal antibodies being developed:
ocrelizumab,
humanized (90%-95% human) B cell-depleting agent.
ofatumumab (HuMax-CD20)...
